It was a pleasure to talk to Professor Andrew Menzies-Gow (Royal Brompton Hospital and Imperial College, London, UK) around his recent analysis of the NAVIGATOR data, investigating the effect of tezepelumab in OCS-dependent severe asthma patients (Clinical Trial Identifier: NCT03347279).
The abstract ‘Effect of Tezepelumab in Oral Corticosteroid-Dependent Patients with Severe Asthma: Results From the Phase 3 NAVIGATOR Study.‘ (ABSTRACT NUMBER: A1442) was presented at ATS 2021 International Conference, 14-19 May, 2021.
- What adverse events are associated with long-term maintenance oral corticosteroids (mOCS) in patients with severe asthma and how does this impact on quality of life and healthcare costs? (0:10)
- What is the rationale for the use of tezepelumab in the treatment of patients with severe asthma? (1:16)
- What have the PATHWAY and NAVIGATOR studies taught us about the efficacy and safety of tezepelumab in this indication? (2:06)
- Could you tell us a little about the objectives and design of your recent analysis of the NAVIGATOR data? (2:45)
- What were the findings of this analysis and what are their implications for patients with severe, OCS-dependent asthma? (3:36)
Disclosures: Andrew Menzies-Gow has participated in research with Astra Zeneca for which his institution has been renumerated and attended advisory boards, has consultancy agreements with and received speaker fees from Astra Zeneca.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Victoria Jones.
Filmed as a highlight of ATS 2021 (Virtual).
Share this Video
Related Videos In Asthma
Antonio Spanevello: Research Highlights from 2021
We were delighted to talk with our Editorial Board member Professor Antonio Spanevello (University of Insubria, Varese, Italy) around his research highlights from 2021 in the field of airway inflammation and asthma. Question Is the evaluation of airway inflammation important in detecting the different phenotypes of bronchial asthma? (0:26) Disclosures: Antonio Spanevello has nothing to […]
Njira Lugogo, CHEST 2021: Tezepelumab for the Treatment of Severe, Uncontrolled Asthma
It was a pleasure to meet with Professor Njira Lugogo (University of Michigan, Ann Arbor, MI, USA) to discuss the findings from the NAVIGATOR study, investigating tezepelumab in adults and adolescents with severe, uncontrolled asthma (NCT03347279). The abstract ‘TEZEPELUMAB PRODUCES CLINICALLY MEANINGFUL RESPONSES ON PATIENT-REPORTED OUTCOME MEASURES IN PATIENTS WITH SEVERE, UNCONTROLLED ASTHMA: RESULTS FROM […]
Njira Lugogo, CHEST 2021: Updates in Asthma Treatment
We were delighted to catch up with Professor Njira Lugogo (University of Michigan, Ann Arbor, MI, USA) around her presentation ‘Asthma Management: New Insights’, which was presented at CHEST 2021, 17-20 October 2021. Questions What has recent research taught us about the heterogeneity of asthma? (0:12) What are the most promising potential future biomarkers for […]
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!